Published in J Pharmacol Exp Ther on January 13, 2009
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther (2011) 1.14
The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther (2009) 1.01
Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One (2009) 0.96
Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J (2012) 0.86
Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. Pharmacogenomics J (2011) 0.82
Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics (2010) 0.80
Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. Pharmacogenomics (2009) 0.80
Contribution of the IBD5 locus to inflammatory bowel disease: a meta-analysis. Hum Genet (2011) 0.79
Identification and Functional Characterization of Novel Genetic Variations in the OCTN1 Promoter. Korean J Physiol Pharmacol (2014) 0.78
Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci (2013) 0.78
Identification of OCTN2 variants and their association with phenotypes of Crohn's disease in a Korean population. Sci Rep (2016) 0.77
Association study between OCTN1 functional haplotypes and Crohn's disease in a Korean population. Korean J Physiol Pharmacol (2016) 0.75
Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency. Mol Genet Metab Rep (2014) 0.75
A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet (2003) 26.59
Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet (2004) 5.83
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet (2003) 4.61
Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. Genome Res (2005) 3.85
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther (2007) 2.80
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica (2006) 1.96
The SLC22 drug transporter family. Pflugers Arch (2003) 1.95
Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet (2005) 1.57
Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease. Eur J Hum Genet (2007) 1.48
Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther (2007) 1.16
Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos (2007) 1.15
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem (2000) 1.11
Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation (2006) 1.09
Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis (2003) 1.08
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist (2006) 1.03
Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics (2007) 1.02
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol (2001) 1.02
Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol Genet Metab (2001) 1.01
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol (2006) 1.00
Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol (2006) 1.00
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos (2008) 0.95
Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet (2008) 0.91
Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol (2008) 0.89
Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. Br J Nutr (2007) 0.87
Mechanism of the regulation of organic cation/carnitine transporter 1 (SLC22A4) by rheumatoid arthritis-associated transcriptional factor RUNX1 and inflammatory cytokines. Drug Metab Dispos (2006) 0.86
Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Drug Metab Pharmacokinet (2008) 0.85
Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. Drug Metab Pharmacokinet (2008) 0.82
Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther (2008) 0.82
Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency. J Mol Cell Cardiol (1998) 0.79
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet (2009) 5.93
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Visualizing density maps with UCSF Chimera. J Struct Biol (2006) 5.75
BayGenomics: a resource of insertional mutations in mouse embryonic stem cells. Nucleic Acids Res (2003) 4.83
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res (2004) 4.54
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet (2008) 4.33
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature (2010) 3.90
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Genome mapping on nanochannel arrays for structural variation analysis and sequence assembly. Nat Biotechnol (2012) 3.43
The International Gene Trap Consortium Website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res (2006) 3.40
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet (2009) 3.33
Population stratification confounds genetic association studies among Latinos. Hum Genet (2005) 3.19
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Designed divergent evolution of enzyme function. Nature (2006) 3.09
Genetic admixture and asthma-related phenotypes in Mexican American and Puerto Rican asthmatics. Genet Epidemiol (2005) 3.03
Using sequence similarity networks for visualization of relationships across diverse protein superfamilies. PLoS One (2009) 3.03
ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res (2010) 2.96
Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet (2007) 2.91
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
Sequence variations in the public human genome data reflect a bottlenecked population history. Proc Natl Acad Sci U S A (2002) 2.70
Adrenoceptor polymorphisms and the risk of cardiac injury and dysfunction after subarachnoid hemorrhage. Stroke (2006) 2.68
Leveraging enzyme structure-function relationships for functional inference and experimental design: the structure-function linkage database. Biochemistry (2006) 2.65
Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med (2004) 2.62
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet (2010) 2.61
clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics (2011) 2.56
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Population structure, admixture, and aging-related phenotypes in African American adults: the Cardiovascular Health Study. Am J Hum Genet (2005) 2.41
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics (2006) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Next generation genome-wide association tool: design and coverage of a high-throughput European-optimized SNP array. Genomics (2011) 2.31
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Software extensions to UCSF chimera for interactive visualization of large molecular assemblies. Structure (2005) 2.12
UCSF Chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol (2011) 2.10
The concentrative nucleoside transporter family, SLC28. Pflugers Arch (2003) 2.06
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A (2003) 2.03
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Recommendations of the 2006 Human Variome Project meeting. Nat Genet (2007) 1.90
Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol (2010) 1.82
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73
Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65
Rapid DNA mapping by fluorescent single molecule detection. Nucleic Acids Res (2006) 1.63
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A (2008) 1.62
Distribution of human SNPs and its effect on high-throughput genotyping. Hum Mutat (2006) 1.59
Association of TGFBR2 polymorphism with risk of sudden cardiac arrest in patients with coronary artery disease. Heart Rhythm (2009) 1.59
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Lack of support for the association between GAD2 polymorphisms and severe human obesity. PLoS Biol (2005) 1.59
Ethnic-specific differences in bronchodilator responsiveness among African Americans, Puerto Ricans, and Mexicans with asthma. J Asthma (2007) 1.57
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 1.57
Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease. Heart Rhythm (2008) 1.56
Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology (2011) 1.52
Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol (2006) 1.51
The Structure-Function Linkage Database. Nucleic Acids Res (2013) 1.50
Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics (2010) 1.48
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci (2006) 1.48